BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28214514)

  • 1. Detecting circulating tumor DNA in renal cancer: An open challenge.
    Corrò C; Hejhal T; Poyet C; Sulser T; Hermanns T; Winder T; Prager G; Wild PJ; Frew I; Moch H; Rechsteiner M
    Exp Mol Pathol; 2017 Apr; 102(2):255-261. PubMed ID: 28214514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
    Ashida S; Okuda H; Chikazawa M; Tanimura M; Sugita O; Yamamoto Y; Nakamura S; Moriyama M; Shuin T
    Clin Cancer Res; 2000 Oct; 6(10):3817-22. PubMed ID: 11051223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma.
    Sumiyoshi T; Yamasaki T; Takeda M; Mizuno K; Utsunomiya N; Sakamoto H; Nakamura E; Ogawa O; Akamatsu S
    Cancer Sci; 2021 Aug; 112(8):3363-3374. PubMed ID: 34009695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma.
    Verhoest G; Patard JJ; Fergelot P; Jouan F; Zerrouki S; Dreano S; Mottier S; Rioux-Leclercq N; Denis MG
    Urol Oncol; 2012; 30(4):469-75. PubMed ID: 20863722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.
    Wolff NC; Pavía-Jiménez A; Tcheuyap VT; Alexander S; Vishwanath M; Christie A; Xie XJ; Williams NS; Kapur P; Posner B; McKay RM; Brugarolas J
    Oncotarget; 2015 Jul; 6(19):16951-62. PubMed ID: 26219258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing of the von Hippel-Lindau gene in canine renal carcinoma.
    Pressler BM; Williams LE; Ramos-Vara JA; Anderson KI
    J Vet Intern Med; 2009; 23(3):592-7. PubMed ID: 19422471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
    Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
    Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. von Hippel-Lindau exonic methylation analysis using MALDI-TOF mass spectrometry.
    Lian F; Sreedharan S; Arnold RS; Master VA; Ogan K; Pattaras JG; Roberts DL; Petros JA
    J Urol; 2014 Nov; 192(5):1528-33. PubMed ID: 24704013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
    Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
    Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel somatic mutations of the VHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cells.
    Rad FH; Ulusakarya A; Gad S; Sibony M; Juin F; Richard S; Machover D; Uzan G
    Am J Hematol; 2008 Feb; 83(2):155-8. PubMed ID: 17696210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Needle core biopsies provide ample material for genomic and proteomic studies of kidney cancer: observations on DNA, RNA, protein extractions and VHL mutation detection.
    Kurban G; Gallie BL; Leveridge M; Evans A; Rushlow D; Matevski D; Gupta R; Finelli A; Jewett MA
    Pathol Res Pract; 2012 Jan; 208(1):22-31. PubMed ID: 22177731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
    Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
    Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective capture of plasma cell-free tumor DNA on magnetic beads: a sensitive and versatile tool for liquid biopsy.
    Kerachian MA; Azghandi M; Javadmanesh A; Ghaffarzadegan K; Mozaffari-Jovin S
    Cell Oncol (Dordr); 2020 Oct; 43(5):949-956. PubMed ID: 32495293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
    Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
    Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.